Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword

被引：3

作者：

Kamrani, Sina ^{[1
]}

Naseramini, Reza ^{[1
]}

Khani, Pouria ^{[2
]}

Razavi, Zahra Sadat ^{[3
]}

Afkhami, Hamed ^{[4
,5
,6
]}

Atashzar, Mohammad Reza ^{[7
]}

Nasri, Farzad ^{[8
]}

Alavimanesh, Sajad ^{[9
,10
]}

Saeidi, Farzane ^{[11
]}

Ronaghi, Hossein ^{[1
]}

机构：

[1] Guilan Univ Med Sci, Fac Med, Dept Orthoped, Rasht, Iran

[2] Univ Tehran Med Sci, Sch Med, Dept Med Genet, Tehran, Iran

[3] Iran Univ Med Sci, Physiol Res Ctr, Tehran, Iran

[4] Qom Univ Med Sci, Cellular & Mol Res Ctr, Qom, Iran

[5] Semnan Univ Med Sci, Nervous Syst Stem Cells Res Ctr, Semnan, Iran

[6] Shahed Univ, Fac Med, Dept Med Microbiol, Tehran, Iran

[7] Fasa Univ Med Sci, Sch Med, Dept Immunol, Fasa, Iran

[8] Iran Univ Med Sci, Sch Med, Dept Immunol, Tehran, Iran

[9] Shahrekord Univ Med Sci, Student Res Comm, Shahrekord, Iran

[10] Shahrekord Univ Med Sci, Basic Hlth Sci Inst, Cellular & Mol Res Ctr, Shahrekord, Iran

[11] Tarbiat Modares Univ, Sch Med Sci, Dept Med Genet, Tehran, Iran

来源：

CANCER CELL INTERNATIONAL | 2025年 / 25卷 / 01期

关键词：

Multiple myeloma; Bone marrow mesenchymal stromal cells; Myeloma progression; DNA-DAMAGE RESPONSE; STEM-CELLS; IN-VITRO; OSTEOGENIC DIFFERENTIATION; LOCALIZED CHEMOTHERAPY; DRUG-RESISTANCE; T-CELLS; GROWTH; PATHOGENESIS; ACTIVATION;

D O I：

10.1186/s12935-025-03741-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Multiple myeloma (MM) is a hematological malignancy defined by the abnormal proliferation and accumulation of plasma cells (PC) within the bone marrow (BM). While multiple myeloma impacts the bone, it is not classified as a primary bone cancer. The bone marrow microenvironment significantly influences the progression of myeloma and its treatment response. Mesenchymal stromal cells (MSCs) in this environment engage with myeloma cells and other bone marrow components via direct contact and the secretion of soluble factors. This review examines the established roles of MSCs in multiple facets of MM pathology, encompassing their pro-inflammatory functions, contributions to tumor epigenetics, effects on immune checkpoint inhibitors (ICIs), influence on reprogramming, chemotherapy resistance, and senescence. This review investigates the role of MSCs in the development and progression of MM.

引用

页数：33

共 308 条

[21] Mesenchymal stromal cells as cancer promoters [J].

Antoon, Roula ;

Overdevest, Nina ;

Saleh, Amr H. ;

Keating, Armand .

ONCOGENE, 2024, 43 (49) :3545-3555

[22] Mesenchymal stem cells inhibit multiple myeloma cells via the Fas/Fas ligand pathway [J].

Atsuta, Ikiru ;

Liu, Shiyu ;

Miura, Yasuo ;

Akiyama, Kentaro ;

Chen, Chider ;

An, Ying ;

Shi, Songtao ;

Chen, Fa-Ming .

STEM CELL RESEARCH & THERAPY, 2013, 4

[23] The Protein Family of Glucose Transport Facilitators: It's Not Only About Glucose After All [J].

Augustin, Robert .

IUBMB LIFE, 2010, 62 (05) :315-333

[24] Mesenchymal Stem Cells and Reticulated Platelets: New Horizons in Multiple Myeloma [J].

Azain, Cristian Alejandro Mera ;

Pasquel, Johan Leandro Vargas ;

Gomez, Sandra Milena Quijano ;

Rodriguez-Pardo, Viviana Marcela .

HEMATOLOGY REPORTS, 2024, 16 (04) :732-741

[25] Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma [J].

Baljevic, Muhamed ;

Zaman, Shadia ;

Baladandayuthapani, Veerabhadran ;

Lin, Yan Heather ;

de Partovi, Claudia Morales ;

Berkova, Zuzana ;

Amini, Behrang ;

Thomas, Sheeba K. ;

Shah, Jatin J. ;

Weber, Donna M. ;

Fu, Min ;

Cleeland, Charles S. ;

Wang, Xin Shelley ;

Stellrecht, Christine M. ;

Davis, Richard E. ;

Gandhi, Varsha ;

Orlowski, Robert Z. .

ANNALS OF HEMATOLOGY, 2017, 96 (06) :977-985

[26] Generation of Induced Pluripotent Stem Cells from Patients with Multiple Myeloma [J].

Basaran, Irem Yilmaz ;

Karaoz, Erdal .

TURKISH JOURNAL OF HEMATOLOGY, 2021, 38 (04) :254-263

[27] Epigenetic Therapies for Cancer [J].

Bates, Susan E. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (07) :650-663

[28]

Bazarbaeva S., 2021, Open Access Macedonian J Med Sci, V9, P753

[29] The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody [J].

Benson, Don M., Jr. ;

Bakan, Courtney E. ;

Mishra, Anjali ;

Hofmeister, Craig C. ;

Efebera, Yvonne ;

Becknell, Brian ;

Baiocchi, Robert A. ;

Zhang, Jianying ;

Yu, Jianhua ;

Smith, Megan K. ;

Greenfield, Carli N. ;

Porcu, Pierluigi ;

Devine, Steven M. ;

Rotem-Yehudar, Rinat ;

Lozanski, Gerard ;

Byrd, John C. ;

Caligiuri, Michael A. .

BLOOD, 2010, 116 (13) :2286-2294

[30] Multiple myeloma cells alter the senescence phenotype of bone marrow mesenchymal stromal cells under participation of the DLK1-DIO3 genomic region [J].

Berenstein, Rimma ;

Blau, Olga ;

Nogai, Axel ;

Waechter, Marlies ;

Slonova, Ekaterina ;

Schmidt-Hieber, Martin ;

Kunitz, Annegret ;

Pezzutto, Antonio ;

Doerken, Bernd ;

Blau, Igor Wolfgang .

BMC CANCER, 2015, 15

← 1 2 3 4 5 6 7 8 9 10 →